Oncology - Pharma Deals News, page-154

Although probable, I feel this is unlikely given the amount of new research going into RNA epigenetic modification.

accent therapeutics formed a partnership for this reason, as they're purely an RNA epigenetic modification company.

given how far advanced we are in this space(as Dr T put it, we have a 50m headstart in a 100m race), the board wouldn't advise us to get bought out without taking into consideration pillar I. And I doubt a big pharma would drop a massive potential in targeted oncology, given the amount of revenue it may achieve.